ALR Technologies SG Ltd. (OTC: ALRTF)

ALR Technologies SG Ltd. develops and markets diabetes management solutions that combine software hardware and data analytics for both human and animal health.

The company generates revenue primarily from the sale of its GluCurve Pet CGM units to distributors and veterinary clinics, as seen in its agreement with Covetrus that produced $25,536 of revenue in 2023. Additionally, the company plans to generate future revenue from its Diabetes Solution platform through device bundles subscription services and licensing agreements with medical providers and health benefit plans.

The company operates through the following segments:

• Diabetes Solution: This segment provides an FDA cleared and HIPAA compliant diabetes management platform that collects glucose data from blood glucose meters and continuous glucose monitors, delivers predictive A1C analytics, and offers insulin dose adjustment recommendations to healthcare providers.

• GluCurve Pet CGM: This segment supplies continuous glucose monitors designed for cats and dogs, paired with a veterinary focused application that uploads glucose readings, creates daily glucose curves, and provides insulin dose calculators and treatment insights.

In the human diabetes management market, ALR Technologies SG Ltd. competes with larger players such as Livongo, Glooko, WellDoc, Medtronic, iGlucose and Microsoft HealthVault, but differentiates itself through FDA clearance, HIPAA compliance, a patent pending predictive A1C algorithm, and a focus on integrating low cost CGM to address data overload, clinical inertia and insulin under prescription.

In the animal health glucose monitoring niche, the company faces competition from established products like AlphaTRAK and off label human CGM devices, yet its GluCurve Pet CGM offers a unique combination of veterinary specific software, automated data uploads and insulin dose support that reduces manual workload for clinics and improves data accuracy.

These advantages position the company to capture share in both markets by delivering clinically validated, cost effective solutions that improve patient outcomes and lower overall care costs.

The company serves veterinary clinics, animal health distributors, and human health providers such as medical clinics, hospitals and health benefit plans, with specific partners including Covetrus for GluCurve distribution, Bionime for bundled glucose meter sales in Singapore, Singapore General Hospital for clinical validation of the Diabetes Solution, and Diabetes Singapore for outreach and education initiatives.